Immune signalling
Thymalin
What is it?
Thymalin is described in the literature as a thymic peptide preparation or complex, rather than a single universally defined synthetic sequence. It is not another name for thymosin alpha-1. The attachment lists TY10 with 10 mg but contains extra notation that is not clear enough to interpret.
How it is studied
Research has investigated immune-cell differentiation and activity. For a peptide mixture, the source tissue, extraction process and composition can affect the biological response. Total mass cannot identify which peptides are present or their relative amounts.
What the evidence shows
A 2020 experimental study examined effects on differentiation of human haematopoietic stem cells and immune-related markers. Human cells in an experiment are not a clinical outcome in patients. Broader literature about thymic preparations involves materials that may differ from this catalogue entry.
Limitations & safety context
The TY10 formulation needs ingredient, identity and source documentation before detailed mechanistic claims can be assigned to it. An immune marker change does not prove disease prevention, rejuvenation or improved resistance to infection. The unclear packaging notation has deliberately not been converted into a claim.
Listed specifications
| Reference | Listed contents |
|---|---|
| TY10 | 10 mg (additional source notation unclear) |
Source-document quantities, not doses or a confirmation of stock. Identity, purity, component composition and suitability require separate documentation.
Research information only. No dosing, administration or treatment advice.